Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 8/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 2/20 | 0.31 |
| ▸ | CTSH | P09668 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522853 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL19576288 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL22788848 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL20809975 | 0.84 | CTSK (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL17326511 | 0.83 | SIRT5 (0.34) | SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL19604383 | 0.83 | C3AR1 (0.42) | SMN1; SMN2POLBKMT2A | |
| SCHEMBL20375823 | 0.82 | DPP7 (0.40) | SMN1; SMN2CTSKCASP1CTSLCTSB | |
| SCHEMBL17346684 | 0.82 | DPP7 (0.40) | SMN1; SMN2CTSKCASP1CTSLCTSB | |
| SCHEMBL23961922 | 0.82 | FURIN (0.34) | SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL20998301 | 0.82 | CTSK (0.38) | SMN1; SMN2CTSKCASP1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | SMN1; SMN2 1994/4885CTSK 1834/4885CASP1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.